Tempest Therapeutics, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Tempest Therapeutics issued approximately $2.5M in securities on September 11, 2026: Common Stock at $0.805/share, Pre-Funded Warrants (exercise price $0.001), Series C Warrants (6-year term, $0.805 exercise price), and Series D Warrants (3-year term, $0.805 exercise price). All warrants exercisable after Stockholder Approval. Placement Agent: H.C. Wainwright Co., LLC. Registration rights granted; lock-up on variable-rate transactions for 60 days post-effectiveness.
Why this rating
Financing is material (8.3% of $30.1M market cap) and dilutive but routine for microcap biotech; no disclosed counterparties, equity structure ordinary; registration rights standard.
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.